Legend Biotech has confirmed that chief executive Ying Huang, Ph.D., has stepped down after six years leading the company.
Alan Bash, who has served as president of Carvykti since 2024, will take the reins as interim CEO while the company searches for a permanent replacement.
Legend stated that Huang’s resignation was not the result of any disagreement with the company, offering little further explanation for the abrupt departure.
Bash’s commercial background leading Carvykti, the CAR-T therapy Legend developed in partnership with Johnson & Johnson, positions him as a steady hand during the transition period.
Merck & Co. briefly published and then deleted details of a phase 2 trial that would combine its PD-1xVEGF bispecific antibody, MK-2010, with its TROP2-directed antibody-drug conjugate, sac-TMT.
The rare glimpse into Merck’s strategy came after nearly two years of silence from the company, which has cited a fiercely competitive market as justification for keeping its PD-1xVEGF plans closely guarded.
Both MK-2010 and sac-TMT were originally developed by Chinese companies, with sac-TMT emerging from Merck’s partnership with Kelun-Biotech.
At an investor event on the sidelines of the 2026 American Society of Clinical Oncology annual meeting, Merck’s head of oncology global clinical development, Marjorie Green, M.D., pointed to the company’s experience combining Keytruda with VEGF inhibitors.
Green touted a “portfolio of novel agents that offer combination opportunities oriented towards combinations of the future rather than adding on to today’s current standard, including ADCs like sac-TMT.”
The deleted trial information surfaced amid growing questions about whether PD-1xVEGF drugs and TROP2 ADCs might compete rather than complement each other in non-small cell lung cancer treatment.
Akeso has reported that ivonescimab achieved head-to-head wins against PD-1 inhibitors in first-line NSCLC, while Kelun-Biotech has also delivered strong phase 3 results for sac-TMT in the same treatment setting.
The FDA has approved Otsuka Pharmaceutical’s Simtriyo, known generically as centanafadine, marking the first approval of a triple norepinephrine, dopamine, and serotonin reuptake inhibitor for attention-deficit/hyperactivity disorder.
Unlike existing treatments such as Adderall or Ritalin, which target two brain chemicals, Simtriyo acts on three, representing a genuinely novel mechanism of action in a crowded therapeutic space.
The approval covers once-daily extended-release capsule use in adults and children aged six and older who weigh at least 20 kg, roughly 44 pounds.
Jefferies analysts described Simtriyo as Otsuka’s “next major CNS launch,” while noting that an upcoming Drug Enforcement Administration scheduling decision will be critical in determining the drug’s commercial ceiling.
Otsuka said the therapy should be available later this year, with potential label expansion into patients with comorbid anxiety likely to follow as the company pursues further clinical development.